Analysts Call Nektar Selloff Unwarranted After Rezpegaldesleukin Durability Data
Off-treatment hair regrowth held in a small group, yet analysts said the Nektar selloff does not change the rezpeg thesis.
Off-treatment hair regrowth held in a small group, yet analysts said the Nektar selloff does not change the rezpeg thesis.
California jury found Lilly breached good faith in the 2017 rezpeg deal and awarded Nektar $90 million plus interest. Lilly plans to appeal.
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.
William Blair upgrades Nektar to Outperform following promising long-term data for rezpegaldesleukin in atopic dermatitis treatment with improved safety profile. The results met and in some cases exceeded investor expectations.